Favezelimab

Favezelimab is a monoclonal antibody that is being investigated for its potential use in the treatment of various autoimmune diseases and cancer. It is designed to target and inhibit specific proteins involved in the immune response, thereby modulating the body's immune system to treat these conditions.

Mechanism of Action

Favezelimab works by targeting the LAG-3 (Lymphocyte-activation gene 3) protein, which is an immune checkpoint receptor. By inhibiting LAG-3, favezelimab can enhance the activity of T cells, which are crucial for the immune response against cancer cells and pathogens. This mechanism is similar to other immune checkpoint inhibitors like nivolumab and pembrolizumab, which target PD-1 and PD-L1 pathways.

Clinical Development

Favezelimab is currently undergoing clinical trials to evaluate its safety and efficacy. These trials are focused on its use in treating various types of cancer, including melanoma, non-small cell lung cancer, and renal cell carcinoma. Additionally, its potential in treating autoimmune diseases such as rheumatoid arthritis and lupus is also being explored.

Potential Benefits

The primary benefit of favezelimab is its ability to enhance the immune system's response to cancer cells, potentially leading to better outcomes for patients with advanced or resistant forms of cancer. In autoimmune diseases, it may help in reducing the overactive immune response that causes tissue damage.

Side Effects

As with other monoclonal antibodies, favezelimab may cause side effects, including fatigue, nausea, diarrhea, and immune-related adverse events such as colitis, hepatitis, and pneumonitis. The safety profile is still being established through ongoing clinical trials.

Related Pages

• Monoclonal antibody
• Immune checkpoint inhibitor
• Cancer immunotherapy
• Autoimmune disease
• LAG-3

See Also

• Nivolumab
• Pembrolizumab
• Ipilimumab
• Atezolizumab

   This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!